COST-EFFECTIVENESS AND BUDGET IMPACT OF SWITCHING FROM A LOWER TO A HIGHER VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN BRAZIL (ID 238)
- Johnna Perdrizet, United States of America
- Johnna Perdrizet, United States of America
- Rodrigo Sini de Almeida, Brazil
- Julia Spinardi, Brazil
Abstract
Background
Brazil has a 10-valent pneumococcal conjugate vaccine (PCV10) pediatric national immunization program (NIP), even though a 13-valent (PCV13) is available and protects against three additional serotypes, 3, 6A, and 19A. Inadvertently, there has been emergence of PCV10 non-vaccine serotypes, notably 19A. We sought to evaluate the cost-effectiveness and budget impact of switching from PCV10 to PCV13 in 2019.
Methods
The analysis estimated future costs ($BRL), quality-adjusted life years (QALYs), and health outcomes for PCV10 and PCV13 NIPs over five years. The adapted model uses local Brazil serotype and Latin America incidence data from 2009-2018. Input parameters are from Brazilian sources. Future serotype dynamics is predicted using Brazilian and global historical trends (Figure 1).
Results
Over five years, switching from PCV10 to PCV13 prevents 176 thousand disease cases and 20 thousand deaths, gains 29 thousand QALYs, and saves 135 million direct and 3 million indirect costs. After one year, 16 million direct healthcare costs are saved by implementing a PCV13 NIP in Brazil.
Conclusions
Despite a higher PCV13 vaccine cost, a PCV13 NIP is cost-saving compared with PCV10, from both societal and payer perspectives. Brazil should consider switching to prevent disease burden, improve population health, and save immediate healthcare costs.